Dopar Articles
Biotie's Parkinson's drug tozadenant clears Phase IIb study
11 December 2012
Drug candidates in pipeline offer potential for Parkinson's disease market, says Frost & Sullivan
9 December 2009
Biovail buys 1730/fipamezole rights in North America from Santhera for $47 million plus $145 million possible royalties
25 August 2009
Safinamide enters Ph III SETTLE trial
11 May 2009
Impax updates on lead candidates
21 April 2009
Japan stock market week to March 16, 2009
23 March 2009
Orion withdraws MAA for expanded Stalevo label
16 March 2009
Azilect helps "double 2nd-line MAO-Bs in PD"
16 March 2009
Safinamide raises "on" time by 1.3 hrs in Ph III trial
9 February 2009
Japan stock market week to Jan 19, 2009
26 January 2009
Orion files suit blocking Wockhardt's generic Stalevo
26 January 2009
Azur buys four drugs from UCB
19 January 2009
Wockhardt seeks to make generic of Orion's Stalevo in USA
15 December 2008
OBM's ProSavin boosts UPDRS up to 50%
24 November 2008
FDA clears two new strengths of Novartis' Stalevo
3 November 2008
Newron granted European patent for safinamide in RLS
20 October 2008
Mylan's generic Parcopa gets FDA OK
29 September 2008
Teva's Azilect meets all endpoints in ADAGIO trial
8 September 2008
FDA approval for GSK
23 June 2008
BI's PD drug finally gets on Australian PBS
16 June 2008
Newron completes Ph III safinamide enrollment
26 May 2008
Orion abandons new COMT inhibitor
19 May 2008
Orion seek broader indication for Stalevo
21 April 2008
Japan stock market week to April 14, 2008
21 April 2008
Eisai ends perampanel PD late-stage program
21 April 2008
Newron says EPO will issue safinamide patent for PD
3 March 2008
FDA says IMPAX' Vadova not approvabale
4 February 2008
Orion/Novartis' Stalevo fares well in Ph III trial
4 February 2008
Santhera/Juvantia's DPD trial enters Ph IIb
26 November 2007
Vectura's inhaled PD drug impresses at Ph II
12 November 2007
Eisai to delay E2007 filing until fiscal 2008
5 November 2007
Newron opens Swiss R&D center in Basel
10 September 2007
Higher dose of Novartis' Stalveo cleared in USA
13 August 2007
Unique benefit profile for Faust's PD drug
11 June 2007
Kyowa Hakko Kogyo files PD drug with FDA
7 May 2007
GSK/SkyePharma file Requip XL with US FDA
23 April 2007
GSK's Requip cuts off time in PD patients
16 April 2007
13 new drugs added to Japan's NHI list
19 March 2007
Neupro patch launched in UK for all stages of PD
29 January 2007
Vernalis' losses for 1st-half 2006 down slightly
18 September 2006
Strong data for Teva/Lundbeck's Azilect as adjunct
11 September 2006
Teva's Azilect approved for early PD in Canada
28 August 2006
Teva and Eisai halt US collaboration on rasagiline
17 July 2006
Mirapexin improves RLS symptoms
26 June 2006
US FDA clears Teva's Azilect for early PD
29 May 2006
Japan stock market week to March 27, 2006
3 April 2006
FDA issues non-appro letter for IMPAX' Vadova
13 March 2006
Orion Pharma sees 37% hike in 2005 profits
20 February 2006
Solvay launches Duodopa in 12 new EU countries
12 September 2005
Mylan sees 12% drop in fourth-qtr profit
23 May 2005
Australian PBS new Rx listings aimed at seniors
11 April 2005
Solvay sees dip in 2004 pharma sales
7 March 2005
Mylan's 3rd-qtr revenues slump 17%
14 February 2005
GB Thera acquires Ph III PD agent from Chiesi
7 February 2005
Valeant moves closer to Zelapar approval
17 January 2005
UPDATE: Neopharma sold to Solvay for $96M
10 January 2005
Avigen initiates Ph I/II trial of AV201
10 January 2005
Solvay makes bid for Sweden's Neopharma
10 January 2005
Orion sees sales fall for first nine months
15 November 2004
Mylan sees sales drop 15% for 2nd qtr
8 November 2004
BI regains pramipexole product portfolio
25 October 2004
KV resolves a handful of legal matters
20 September 2004
Positive data for Teva's Agilect
13 September 2004
FDA approves Schwarz Pharma's Parcopa
13 September 2004
Trial to assess Stalevo in delaying dyskinesia
13 September 2004
FDA approvable letter for Teva's Agilect
12 July 2004
Orion/Abbott expand levosimendan accord
26 April 2004
India cuts 34 import-content bulk Rx prices
8 March 2004
Orion's Stalevo available in the UK
22 December 2003
Avigen files IND with FDA for AV201
17 November 2003
EU clears Orion/Novartis' Stalevo
3 November 2003
Rasagiline reduces "off" time in PD
27 October 2003
Orion and Novartis' Stalevo shows benefits in Parkinson's disease
8 September 2003
Orion's PD therapy is approved by FDA
30 June 2003
India acts on prices of 87 drug formulations
9 June 2003
Merck backs off Impax lawsuit?
14 April 2003
India raises antifungal, Parkinson's drug prices
5 August 2002
Parkinson's drugs may slow progression
22 April 2002
Kyowa says Parkinson's drug trials are promising
25 February 2002
FDA approves Medtronic's Activa for Parkinson's disease.
21 January 2002
Chiesi of Italy sets out expansion plans for rest of Europe
29 November 2001
Pramipexole cleared as monotherapy in PD
26 November 2001
Oxford BioMedica lifted by Parkinson's therapy
13 November 2001
COMT inhibitor make levodopa delivery smoother
31 July 2001
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
